[
    [
        {
            "time": "2020-09-16",
            "original_text": "康泰生物子公司两项疫苗临床试验申请获受理",
            "features": {
                "keywords": [
                    "康泰生物",
                    "疫苗",
                    "临床试验",
                    "申请受理"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "康泰生物子公司两项疫苗临床试验申请获受理",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-09-16",
            "original_text": "康泰生物：五联疫苗临床试验申请获得受理",
            "features": {
                "keywords": [
                    "康泰生物",
                    "五联疫苗",
                    "临床试验",
                    "申请受理"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "康泰生物：五联疫苗临床试验申请获得受理",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-09-16",
            "original_text": "康泰生物（300601.SZ）：两名董事、高管通过大宗交易合计减持42.1万股 减持股份",
            "features": {
                "keywords": [
                    "康泰生物",
                    "董事",
                    "高管",
                    "减持",
                    "大宗交易"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "康泰生物（300601.SZ）：两名董事、高管通过大宗交易合计减持42.1万股 减持股份",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-09-16",
            "original_text": "康泰生物：公司董事刘建凯、副总裁李彤合计减持0.06%股份 减持股份数量",
            "features": {
                "keywords": [
                    "康泰生物",
                    "董事",
                    "副总裁",
                    "减持",
                    "股份数量"
                ],
                "sentiment_score": -0.65,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "康泰生物：公司董事刘建凯、副总裁李彤合计减持0.06%股份 减持股份数量",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-09-16",
            "original_text": "为何康华生物不打造另一款爆款出来，分散单品的集中风险？",
            "features": {
                "keywords": [
                    "康华生物",
                    "爆款",
                    "分散风险",
                    "单品集中风险"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "为何康华生物不打造另一款爆款出来，分散单品的集中风险？",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-09-16",
            "original_text": "生物制药行业2020年1-8月生物制品批签发：稳中有增",
            "features": {
                "keywords": [
                    "生物制药行业",
                    "批签发",
                    "稳中有增"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "生物制药行业2020年1-8月生物制品批签发：稳中有增",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        },
        {
            "time": "2020-09-16",
            "original_text": "新冠疫苗最快11月可接种，A股疫苗能否雄起？",
            "features": {
                "keywords": [
                    "新冠疫苗",
                    "接种",
                    "A股疫苗"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "新冠疫苗最快11月可接种，A股疫苗能否雄起？",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 10,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]